Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 180

1.

Insulin glargine improves hemoglobin A1c in children and adolescents with poorly controlled type 1 diabetes.

Jackson A, Ternand C, Brunzell C, Kleinschmidt T, Dew D, Milla C, Moran A.

Pediatr Diabetes. 2003 Jun;4(2):64-9.

PMID:
14655261
2.

Reduced hypoglycemic episodes and improved glycemic control in children with type 1 diabetes using insulin glargine and neutral protamine Hagedorn insulin.

Chase HP, Dixon B, Pearson J, Fiallo-Scharer R, Walravens P, Klingensmith G, Rewers M, Garg SK.

J Pediatr. 2003 Dec;143(6):737-40.

PMID:
14657818
4.

Initiation of insulin glargine in children and adolescents with type 1 diabetes.

Tan CY, Wilson DM, Buckingham B.

Pediatr Diabetes. 2004 Jun;5(2):80-6.

PMID:
15189493
5.

Basal insulin switch from NPH to glargine in children and adolescents with type 1 diabetes.

Päivärinta M, Tapanainen P, Veijola R.

Pediatr Diabetes. 2008 Jun;9(3 Pt 2):83-90. doi: 10.1111/j.1399-5448.2007.00341.x. Epub 2008 Jan 25.

PMID:
18221431
6.

Comparison of prandial AIR inhaled insulin alone to intensified insulin glargine alone and to AIR insulin plus intensified insulin glargine in patients with type 2 diabetes previously treated with once-daily insulin glargine.

Rosenstock J, Eliaschewitz FG, Heilmann CR, Muchmore DB, Hayes RP, Belin RM.

Diabetes Technol Ther. 2009 Sep;11 Suppl 2:S63-73. doi: 10.1089/dia.2009.0059.

PMID:
19772451
7.

A randomized, controlled trial comparing twice-a-day insulin glargine mixed with rapid-acting insulin analogs versus standard neutral protamine Hagedorn (NPH) therapy in newly diagnosed type 1 diabetes.

Hassan K, Rodriguez LM, Johnson SE, Tadlock S, Heptulla RA.

Pediatrics. 2008 Mar;121(3):e466-72. doi: 10.1542/peds.2007-1679. Epub 2008 Feb 25.

PMID:
18299307
8.

Improved glycemic control without an increase in severe hypoglycemic episodes in intensively treated patients with type 1 diabetes receiving morning, evening, or split dose insulin glargine.

Garg SK, Gottlieb PA, Hisatomi ME, D'Souza A, Walker AJ, Izuora KE, Chase HP.

Diabetes Res Clin Pract. 2004 Oct;66(1):49-56.

PMID:
15364161
9.

Insulin glargine provides greater improvements in glycaemic control vs. intensifying lifestyle management for people with type 2 diabetes treated with OADs and 7-8% A1c levels. The TULIP study.

Blicklé JF, Hancu N, Piletic M, Profozic V, Shestakova M, Dain MP, Jacqueminet S, Grimaldi A.

Diabetes Obes Metab. 2009 Apr;11(4):379-86. doi: 10.1111/j.1463-1326.2008.00980.x. Epub 2008 Dec 14.

PMID:
19087105
10.

Treatment with insulin glargine reduces asymptomatic hypoglycemia detected by continuous subcutaneous glucose monitoring in children and adolescents with type 1 diabetes.

Deiss D, Kordonouri O, Hartmann R, Hopfenmüller W, Lüpke K, Danne T.

Pediatr Diabetes. 2007 Jun;8(3):157-62.

PMID:
17550426
11.

Glycemic control with insulin glargine as part of an ethnically diverse, community-based diabetes management program.

Philis-Tsimikas A, Zhang Q, Walker C.

Am J Ther. 2006 Nov-Dec;13(6):466-72.

PMID:
17122525
12.

Reduced severe hypoglycemia with insulin glargine in intensively treated adults with type 1 diabetes.

Garg SK, Paul JM, Karsten JI, Menditto L, Gottlieb PA.

Diabetes Technol Ther. 2004 Oct;6(5):589-95.

PMID:
15628812
13.

Glycemic variation and hypoglycemia in patients with well-controlled type 1 diabetes on a multiple daily insulin injection program with use of glargine and ultralente as basal insulin.

Kudva YC, Basu A, Jenkins GD, Pons GM, Vogelsang DA, Rizza RA, Smith SA, Isley WL.

Endocr Pract. 2007 May-Jun;13(3):244-50.

PMID:
17599855
14.

Effect of therapy with insulin glargine (lantus) on glycemic control in toddlers, children, and adolescents with diabetes.

Hathout EH, Fujishige L, Geach J, Ischandar M, Maruo S, Mace JW.

Diabetes Technol Ther. 2003;5(5):801-6.

PMID:
14633345
15.

[Switching of NPH insulin to glargine therapy in a cohort of diabetic patients: observational study].

Maia FF, Melo FJ, Araújo IM, Araújo LR.

Arq Bras Endocrinol Metabol. 2007 Apr;51(3):426-30. Portuguese.

16.

Addition of neutral protamine lispro insulin or insulin glargine to oral type 2 diabetes regimens for patients with suboptimal glycemic control: a randomized trial.

Esposito K, Ciotola M, Maiorino MI, Gualdiero R, Schisano B, Ceriello A, Beneduce F, Feola G, Giugliano D.

Ann Intern Med. 2008 Oct 21;149(8):531-9.

PMID:
18936501
17.

Therapy with insulin glargine (Lantus) in toddlers, children and adolescents with type 1 diabetes.

Colino E, López-Capapé M, Golmayo L, Alvarez MA, Alonso M, Barrio R.

Diabetes Res Clin Pract. 2005 Oct;70(1):1-7. Epub 2005 Mar 2.

PMID:
16126116
18.

Insulin glargine versus intermediate-acting insulin as the basal component of multiple daily injection regimens for adolescents with type 1 diabetes mellitus.

Chase HP, Arslanian S, White NH, Tamborlane WV.

J Pediatr. 2008 Oct;153(4):547-53. doi: 10.1016/j.jpeds.2008.04.063. Epub 2008 Jun 27.

PMID:
18589448
19.

Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients.

Rosenstock J, Sugimoto D, Strange P, Stewart JA, Soltes-Rak E, Dailey G.

Diabetes Care. 2006 Mar;29(3):554-9.

PMID:
16505505
20.

Clinical outcomes using long-term combination therapy with insulin glargine and exenatide in patients with type 2 diabetes mellitus.

Levin PA, Mersey JH, Zhou S, Bromberger LA.

Endocr Pract. 2012 Jan-Feb;18(1):17-25. doi: 10.4158/EP11097.OR.

PMID:
21742605

Supplemental Content

Support Center